Conjunctivitis

• EMA approval · 2026-01-15
  EMA Authorised: Verkazia (ciclosporin) — Santen Oy

  EMA has authorised Verkazia (ciclosporin) from Santen Oy for the treatment of conjunctivitis and keratitis. The product has orphan medicinal…

• FDA approval · 2025-09-30
  FDA Approved: NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE — Original Application (Amneal Pharmaceuticals NY LLC)

  FDA approved Amneal Pharmaceuticals NY LLC's original ANDA for Neomycin and Polymyxin B Sulfates and Hydrocortisone, a combination antibioti…

• FDA approval · 2024-01-09
  FDA Approved: FLUOROMETHOLONE OPHTHALMIC SUSPENSION — Original Application (Amneal Pharmaceuticals NY LLC)

  FDA approved Amneal Pharmaceuticals NY LLC’s fluorometholone ophthalmic suspension under an Original Application (ANDA216348).

• FDA approval · 2023-07-21
  FDA Approved: NEOMYCIN POLYMYXIN B SULFATES AND DEXAMETHASONE — Supplemental Application (Bausch & Lomb Incorporated)

  FDA approved a supplemental application for Neomycin sulfate, polymyxin B sulfate, and dexamethasone ophthalmic suspension from Bausch & Lom…

• FDA approval · 2021-12-10
  FDA Approved: MAXIDEX — Supplemental Application (Harrow Eye, LLC)

  FDA approved a supplemental application for MAXIDEX (dexamethasone) by Harrow Eye, LLC.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• FDA approval · 2021-03-25
  FDA Approved: CARBINOXAMINE MALEATE EXTENDED-RELEASE ORAL SUSPENSION — Supplemental Application (Neos Therapeutics, LP)

  FDA approved a supplemental application to authorize an extended-release oral suspension formulation of carbinoxamine maleate, submitted by …

• FDA approval · 2018-06-06
  FDA Approved: PRED MILD — Supplemental Application (Allergan, Inc.)

  FDA approved a supplemental application for PRED MILD (prednisolone acetate) by Allergan, Inc., adding a supplemental approval for this opht…

• FDA approval · 2016-03-10
  FDA Approved: MAXIDEX — Supplemental Application (Harrow Eye, LLC)

  FDA approved a supplemental application for MAXIDEX (dexamethasone) from Harrow Eye, LLC.

• FDA approval · 2013-12-16
  FDA Approved: LOTEPREDNOL ETABONATE — Supplemental Application (Bausch & Lomb Americas Inc.)

  The FDA approved a supplemental application for Loteprednol Etabonate (Lotemax) from Bausch & Lomb Americas Inc.

• FDA approval · 2013-02-12
  FDA Approved: FML — Supplemental Application (Allergan, Inc.)

  FDA approved Allergan's supplemental application for FML (fluorometholone), resulting in updated labeling for the ophthalmic corticosteroid.

• FDA approval · 2010-06-03
  FDA Approved: LOTEPREDNOL ETABONATE AND TOBRAMYCIN — Supplemental Application (Bausch & Lomb Americas Inc.)

  FDA approved a supplemental application for Loteprednol etabonate and tobramycin, expanding labeling to treat inflammatory ocular conditions…

• FDA approval · 2009-03-20
  FDA Approved: DIFLUPREDNATE OPHTHALMIC — Supplemental Application (Sandoz Inc)

  FDA approved Sandoz Inc's supplemental application for difluprednate ophthalmic, approving a generic corticosteroid ophthalmic solution for …